These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Fever following administration of two inactivated influenza vaccines--a survey of parents of New Zealand infants and children 5 years of age and under.
    Author: Petousis-Harris H, Poole T, Booy R, Turner N.
    Journal: Vaccine; 2011 Apr 05; 29(16):2933-7. PubMed ID: 21338679.
    Abstract:
    UNLABELLED: Due to a dramatic increase in reported febrile convulsions in Western Australia following a routine pediatric influenza vaccination programme we evaluated parental recall of fever in their child following 2010 trivalent influenza vaccine manufactured by either Sanofi Pasteur (Vaxigrip(®)) or CSL Biotherapies (Fluvax(®)) to determine if the rates of febrile events in infants and children 5 years and under following administration of either Vaxigrip(®) or Fluvax(®) were significantly different. METHOD: A convenience sample of New Zealand General practices who had received stocks of the vaccines of interest consecutively contacted parents of infants and children under 5 years of age who received at least one dose of 2010 influenza vaccine. A brief questionnaire was administered with the main outcome parental recall of fever within 24 h of vaccination. RESULTS: Response rate was 99%. There were 327 parents of children aged 6 months to 5 years attending one of 23 primary care practices who had received a dose of either the Vaxigrip(®) or Fluvax(®) vaccine between 4th March and 28th June 2010 surveyed. A total of 422 doses were given of which 267 were Vaxigrip(®), 133 were Fluvax(®) and 22 another vaccine. Fever occurred significantly more frequently within 24 h following administration of Fluvax(®) compared with Vaxigrip(®) RR 4.33 (2.44-7.70). When fevers were measured they were, on average, higher in the Fluvax(®) vaccines (38°C compared with 39°C). Additionally, recipients were more likely to seek medical advice for fever following Fluvax(®) RR 23.11 (2.96-180.12). CONCLUSIONS: There is considerable variation in reactogenicity between two 2010 seasonal vaccines in infants and young children. Vaxigrip(®) is significantly less reactogenic when compared to Fluvax(®) in this population in which Fluvax(®) is associated with unacceptably high rates of febrile reactions. There has been insufficient safety evaluation of seasonal influenza vaccine safety in this population.
    [Abstract] [Full Text] [Related] [New Search]